Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

MEK (Mitogen-activated protein kinase kinase) inhibitors & Plexiform Neurofibromas (PN) / Neurofibroma

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

MEK (Mitogen-activated protein kinase kinase) inhibitors are now a core systemic treatment class for NF1-associated symptomatic, inoperable plexiform neurofibromas (PN), with the strongest clinical and regulatory support for selumetinib and mirdametinib rather than for “neurofibroma” broadly as a single group.
Kotch et al. 2026 Neuro-Oncology Advances 8(Suppl_2): ii14–ii24

see also:
Plexiform Neurofibromas (PN) / Neurofibroma & Drugs/Treatments
[Selumetinib & Plexifor…

References (Sources)

MEK inhibitors for neurofibromatosis type 1-associated central and peripheral nervous system tumors
Kotch et al. 2026 Neuro-Oncology Advances 8(Suppl_2): ii14–ii24

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!

MEK (Mitogen-activated protein kinase kinase) inhibitors & Plexiform Neurofibromas (PN) / Neurofibroma

Welcome to meRfi Microbiome!

Navigation

Contents

References (Sources)

AI Chat